1286739-19-2

Basic information

• Product Name: 6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one
• Synonyms: 6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one;FRAX597;Pyrido[2,3-d]pyriMidin-7(8H)-one, 6-[2-chloro-4-(5-thiazolyl)phenyl]-8-ethyl-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]-;6-(2-chloro-4-(thiazol-5-yl)phenyl)-8-ethyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one;FRAX597, >=98%;6-[2-Chloro-4-(5-thiazolyl)phenyl]-8-ethyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one
• CAS NO: 1286739-19-2
• Molecular Formula: C₂₉H₂₈ClN₇OS
• Molecular Weight: 558.09692
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 1286739-19-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly)
• CAS DataBase Reference: 6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one(1286739-19-2)
• EPA Substance Registry System: 6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one(1286739-19-2)

Safety Data

• Hazardous Substances Data: 1286739-19-2(Hazardous Substances Data)

Usage

Description

6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one is a complex organic compound with a unique molecular structure. It is characterized by its thiazol and pyrimidinone moieties, which contribute to its potential biological activities and applications in various fields.

Uses

Used in Pharmaceutical Industry:
6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one is used as a potential therapeutic agent for the treatment of various diseases, including cancer. Its unique molecular structure allows it to interact with specific cellular targets, such as p21-activated kinases (Paks), which play a crucial role in cellular signaling pathways and are implicated in oncogenic processes.
Used in Cancer Treatment:
6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one is used as a PAK1 inhibitor for the treatment of pancreatic cancer. When used in combination with Gemcitabine (G305000), an antineoplastic agent, it can significantly reduce pancreatic cancer growth by inhibiting the oncogenic kinases and disrupting the cellular signaling pathways that promote tumor progression.
Used in Drug Development:
6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one is also used in the development of novel drug delivery systems to enhance its bioavailability and therapeutic outcomes. By employing various organic and metallic nanoparticles as carriers, the compound can be more effectively delivered to cancer cells, improving its overall efficacy and potentially leading to better treatment outcomes for patients.

Biological Activity

frax597 is a small-molecule inhibitor of the group 1 p21-activated kinases (paks) with ic50 values of 8nm, 13nm and 19nm, respectively for pak1, pak2 and pak3 [1].the paks family includes two sub groups: 1 and 2. these kinases take participate in the growth of various types of cancers. frax597 is developed to be an inhibitor of group 1 paks from the initial hits of a high throughput screen. it is an atp-competitive inhibitor of pak 1-3. to group 2 paks, frax597 shows minimal inhibitory activity. the inhibition mechanism of frax597 is that it binds pak by targeting the atp binding site and competes with atp. frax597 is reported to suppress cell proliferation by arresting cell cycle in g1 without impacting cell viability in schwann cells. in vivo assay also demonstrates frax597 can suppress tumor growth in an orthotopic model of nf2. this effect on the cells has been proved to be mediated through the inhibition of the group i paks [1].

references

[1] silvia licciulli, jasna maksimoska, chun zhou, scott troutman, smitha kota, qin liu, sergio duron, david campbell, jonathan chernoff, jeffery field, ronen marmorstein and joseph l. kissil. frax597, a small molecule inhibitor of the p21-activated kinases, inhibits schwannomas tumorigenesis of nf2-associated. j. biol. chem. 2013, august.

Relevant articles and documents

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.